Q-omics provides the consensus-scored MST1L profile across patient tissues and cancer cell-line models. MST1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MST1L is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MST1L RNA expression shows 14,402 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where MST1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MST1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MST1L survival associations across molecular data types. MST1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MST1L RNA expression–survival associations across cancer types. High MST1L expression shows unfavorable associations in ESCA, DLBC and LGG, but favorable associations in BLCA, BRCA and MESO. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for MST1L RNA expression.
This table summarizes MST1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MST1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MST1L shows lower tumor expression in KIRC, KICH, KIRP, COAD, LUSC and BRCA. The KIRC box plot shows higher MST1L RNA expression in normal versus tumor tissue (log2 FC = −3.044, t-test p < 0.001).
This table shows molecular features associated with MST1L in patient tissues and cancer cell lines. In patient samples, MST1L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MST1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and NCI60_ALL.
